X4 Pharmaceuticals, Inc cotiza a 2.82 USD y tiene una capitalización bursátil de $280M. En los últimos 12 meses ha facturado $9M con un margen de flujo de caja libre del -1317.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical tr…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.13 | $-0.16 | $-0.22 |
| Estimado | $-0.19 | $-0.18 | $-0.20 | $-0.35 |
| Sorpresa | — | +27.8% | +20.0% | +37.1% |
| Métrica | XFOR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 11.4% | 57.0% | -45.6% |
| Operating Margin | -1336.7% | -38.6% | -1298.0% |
| Net Margin | -1218.5% | -33.6% | -1184.9% |
| FCF Margin | -1317.2% | -13.9% | -1303.3% |
| ROE | -42.5% | -40.4% | -2.1% |
| ROA | -27.3% | -32.0% | +4.7% |
| Current Ratio | 10.16 | 2.84 | +7.32 |
| Debt / Equity | 0.40 | 0.28 | +0.12 |